The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Measured by its ability to bind recombinant rat VEGF C in a functional solid phase binding assay. Immobilised recombinant human sVEGFR 3/Fc at 5 µg/ml can bind recombinant rat VEGF-C in a linear range of 8-500 ng/ml.
% SDS-PAGE. Purity assessed by SDS page followed by Silver stain.
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
This product is an active protein and may elicit a biological response in vivo, handle with caution.
Reconstitute in PBS or medium to a concentration not lower than 100 µg/ml.
Receptor for VEGFC. Has a tyrosine-protein kinase activity.
Placenta, lung, heart, and kidney, does not seem to be expressed in pancreas and brain.
Involvement in disease
Defects in FLT4 are the cause of lymphedema hereditary type 1A (LMPH1A) [MIM:153100]; also known as Nonne-Milroy lymphedema or Milroy disease. Hereditary lymphedema is a chronic disabling condition which results in swelling of the extremities due to altered lymphatic flow. Patients with lymphedema suffer from recurrent local infections and physical impairment. Note=Defects in FLT4 are found in juvenile hemangioma. Juvenile hemangiomas are the most common tumors of infancy, occurring as many as 10% of all births. These benign vascular lesions enlarge rapidly during the first year of life by hyperplasia of endothelial cells and attendant pericytes, and then spontaneously involute over a period of years, leaving loose fibrofatty tissue.
Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily. Contains 7 Ig-like C2-type (immunoglobulin-like) domains. Contains 1 protein kinase domain.